N/A N=106,629 Effects of Code Sepsis Implementation on Emergency Department (ED) Sepsis Care
Sepsis
Primary: Door-to-antibiotic Time — 160; 146; 139; 140 minutes — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=28 Sepsis-Associated Purpura Fulminans International Registry - Europe
Sepsis
Primary: Mortality — 11 Participants
N/A N=185 Algorithm for Predicting the Unfavorable Course of Sepsis in Children
Sepsis
Primary: Blood Leukocyte Subpopulations: the Absolute Numbers of Leukocytes of Specific Phenotypes — 16.0; 11.2; 11.9; 4.9 10^9 cells/l — p=<0.05
N/A N=22 Piperacillin PK Analysis in Severe Sepsis Patients
Sepsis · Severe Sepsis
Primary: 100% f T>MIC: Free Piperacillin Concentration Maintained Above the MIC Throughout the Dosing Interval. — 4 participants
Phase 1 N=31 A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.
Severe Sepsis
Primary: Percentage of Incidence Rates of Serious Adverse Events (SAEs), Adverse Events (AEs), Immune-mediated AEs, AEs Leading to Discontinuation, and Deaths — 6.7; 43.8; 93.3…
N/A N=226 Utility of Presepsin in Distinguishing Between Sepsis and SIRS
SIRS · Sepsis
Primary: Area Under the Receiver Operating Characteristic Curve (ROC-AUC) of the Plasma Presepsin Concentration for Discriminating Between SIRS and Sepsis — 0.7218; 0.6901…
Phase 2 N=120 Vitamin C & Thiamine to Treat Sepsis and Septic Shock
Sepsis · Septic Shock
Primary: Mortality Rates — 12; 7 Participants — p=0.344
Phase 2 N=1,379 GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
Sepsis
Primary: Percentage of Participants With 28-Day All Cause Mortality — 26.9; 25.8; 31.3 Percentage of participants — p=0.329
Phase 2 N=72 Citrulline in Severe Sepsis
Severe Sepsis · Acute Lung Injury
Primary: Vasopressor Dependency Index — 50.0; 44.4; 49.0 mmHg/catecholamine index — p=0.86
Phase 3 N=30 Cholecalciferol Supplementation for Sepsis in the ICU
Hypovitaminosis D
Primary: Change in Vitamin D Status 5 Days Following Supplementation With Cholecalciferol — 19; 15; 17; 19 ng/mL
Phase 2 N=140 Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis.
Sepsis, Severe · Septic Shock
Primary: Time to Vasopressor Independence (Hours) — 27; 53 hours — p=<0.001
Phase 2 N=488 Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery
Acute Respiratory Distress Syndrome · Critical Illness · Respiratory Failure
Primary: Days Alive and Free of Organ Support to Day 28 — 20.2; 20.5; 19.7; 18.4 days — p=0.65
N/A N=458 Venous Lactate in Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients in Emergency Department
Sepsis · Disease Progression · Septic Shock
Primary: Proportion of the Patients Who Require Vasopressor/Mechanical Ventilator — 53; 21 participants
Phase 4 N=2,634 Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
Sepsis · AKI · Neurotoxicity
Primary: Acute Kidney Injury (AKI) Ordinal Scale — 910; 952; 86; 100 Participants
Phase 2 N=44 Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis
Severe Sepsis
Primary: F2-isoprostanes After 72 Hours of Acetaminophen or Placebo — 33.4; 40.15 pg/mL — p=0.353
N/A N=142 Preemptive Resuscitation for Eradication of Septic Shock
Sepsis · Severe Sepsis
Primary: Number of Participants With Worsening Organ System Dysfunction Defined by SOFA Score Increase ≥ 1 — 34; 20 Participants — p=0.064
Phase 2 N=24 Ascorbic Acid (Vitamin C) Infusion in Human Sepsis
Sepsis · Septic Shock · Hypotension
Primary: Number of Patients Who Experienced Ascorbic Acid Infusion Related Arterial Hypotension, Vomiting, or Tachycardia in Septic Patients — 0; 0; 0 participants
Phase 3 N=125 Vitamin C and Septic Shock
Septic Shock · Sepsis
Primary: Number of Participants With ICU Mortality — 20; 14 Participants
Phase 2 N=167 Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury
Acute Lung Injury · Sepsis
Primary: Modified Change in Sequential Organ Failure Assessment (mSOFA) Score — -2.96; -3.20 score on a scale
N/A N=18,693 Paediatric Rapid Sepsis Trigger (PRST) Tool
Sepsis · Infection
Primary: Time to Administration of an Appropriate Antimicrobial — 115; 123; 239; 261 minutes
Phase 2 N=12 Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock
Severe Sepsis · Septic Shock
Primary: Evaluate the Safety Profile of Pioglitazone in Patients With Severe Sepsis and Septic Shock as the Number of Hypoglycemic Events — 0; 0 events — p=1.0
N/A N=73 Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS
Sepsis
Primary: Delta Curve Between Calculated GFR and GFR Measured by Iohexol at Baseline — 91.5; 88.3; 93.6; 90.0 ml/min/1.73m2 — p=<0.05
Phase 3 N=1,696 Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock
Sepsis
Primary: 28-Day All-Cause Mortality — 26.4; 24.2 percentage of participants — p=0.313
Phase 2 N=56 Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
Bacteremia · Staphylococcus Aureus · Staphylococcus Aureus Bacteremia
Primary: Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability) Following Multiple Doses of Intravenous AP-Sa02. — 17; 10; 6; 2 number of…
N/A N=450 Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock
Septic Shock · Endotoxemia
Primary: Mortality — 78; 84 Participants
N/A N=30 A Randomized Controlled Trial of a Conservative Fluid Balance Strategy for Patients With Sepsis and Cardiopulmonary Dysfunction (BALANCE Study)
Sepsis
Primary: ICU-free Days to 14 Days After Enrollment — 9; 11 days
N/A N=1,351 Protocolized Care for Early Septic Shock
Sepsis · Severe Sepsis · Septic Shock
Primary: Hospital Mortality — 92; 81; 86 Participants
N/A N=21 Inflammatory Cytokine Quantification in Infants
Sepsis · Congenital Diaphragmatic Hernia · Neonatal Cardiopulmonary Failure
Primary: TNF-alpha, Baseline — 8.88 pg/mL
Phase 2 N=20 A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock
Severe Sepsis · Septic Shock
Primary: Safety and Tolerability of AZD9773 — 7; 7; 6; 1 Participants
N/A N=3,230 Effect of Emergency Department Care Reorganization on Door-to-antibiotic Times for Sepsis (LDS SWARM)
Septic Shock · Sepsis
Primary: Time From ED Arrival to Administration of First Dose of Antibiotics — 173; 165; 169; 163 minutes — p=0.29